CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial CuraAX Designed to Treat Neurogenic Orthostatic Hypotension (nOH) and Cognitive Impairment San Carlos, CA – February 20, 2025 – CuraSen Therapeutics, Inc., a...
Kyruus Health Achieves Record Growth as Searches for Care Surpass 1 Billion Care access leader adds 12M health plan members and 100 new provider organizations to its platform BOSTON, MA – FEB. 5, 2024 – Kyruus Health delivered record-breaking growth in 2024,...
Kyruus Health and aha! Announce Partnership to Enhance Patient Access and Engagement UCI Health Leads the Way in Patient-Centric Digital Experiences with Kyruus Health and aha! Partnership BOSTON, MA – FEB. 13, 2024 – Kyruus Health, the leading care access platform,...
Bluesight Expands Compliance Capabilities and Strengthens Platform through Acquisition of Protenus ALEXANDRIA and BALTIMORE, January 9, 2025 – Bluesight, the leading provider of inventory management, procurement, and compliance solutions for health systems and...
Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular Hypertension QLS-111 met all primary and secondary endpoints in the Osprey and Apteryx studies QLS-111 added to latanoprost drove up...
Recent Comments